Reactivation of hepatitis B during immunosuppressive therapy: Potentially fatal yet preventable

Annals of Internal Medicine

Volumn 156, Issue 10, 2012, Pages 743-746

  Lok, Anna S F ^a   Ward, John W ^b   Perrillo, Robert P ^c   McMahon, Brian J ^d   Jake Liang, T ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^e American Association for the Study of Liver Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; VIRUS DNA;

ARTICLE; CANCER CHEMOTHERAPY; DEATH; FALSE POSITIVE RESULT; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY AND SPECIFICITY; VIRUS REACTIVATION;

EID: 84861119867     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-10-201205150-00013     Document Type: Article

References (20)

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-65.
2. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299-307.
3. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021-9.
4. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246-52.
5. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170-80.
6. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519-28.
7. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47:844-53.
8. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50:661-2. Accessed at www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf on 5 April 2012.
10. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150:104-10.
11. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol. 2000; 62:450-5.
12. Leung C, Tsoi E, Burns G, Sievert W. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist. 2011;16:579-84.
13. Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther. 2010;31:240-6.
14. Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract. 2011;7:141-7.
15. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Pr; 2010. Accessed at www.iom.edu/Reports/2010/Hepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C.aspx on 5 January 2012.
16. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010;28:3199-202.
17. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.
18. Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken). 2010;62:704-11.
19. McQuillan GM, Townsend TR, Johannes CB, Dillard T, Molteni RA, Ness PM, et al. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am J Epidemiol. 1987;126:484-91.
20. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, Mc- Quillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202:192-201.